entertainment -WSS

entertainment

author：entertainment 2025-08-20 09:42:17 - browse：2296

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： How clinical AI models' predictive power can degrade over time

hotspot

WSS

Cancer cells are shown to suck energy source from immune cells

UnitedHealth increases loan offers after Change Healthcare outage

Neuroscience’s long legacy of racism

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

What the Wegovy shortage looks like for doctors — and for patients

UnitedHealth increases loan offers after Change Healthcare outage

leisure time

entertainment

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Virtual Event: March of the Biosimilars

Hepatitis C has a cure — but many Americans still lack access to it

How doctors and nurses shape Google's AI

DIEP, the 'gold standard' of breast reconstruction, is under threat

Nurses recount patients attacks

After affirmative action ruling, medical educators look to 'holistic review'

Bernie Sanders bashes nonprofit hospitals over their tax breaks

After affirmative action ruling, medical educators look to 'holistic review'

Health AI adoption puts security, privacy startups on investors' radar

focus

European regulators consider appeal over Amylyx ALS drug

How should state employee insurance handle Wegovy?

U.K. researchers warn about biases in medical devices, algorithms

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

European regulators recommend Amylyx's ALS drug be rejected

Physicians and social media: If you see something, say something?

hotspot

hotspot

leisure time

entertainment